Apogee Therapeutics, INC

Apogee Therapeutics shareholders re-elected three directors and ratified the appointment of Ernst & Young LLP as independent auditor.

Apogee Therapeutics announced a strategic financing collaboration with Blackstone Life Sciences, providing up to $1.3 billion in non-dilutive capital to advance its lead drug zumilokibart.

Apogee Therapeutics reported positive 16-week induction dose optimization results from its Phase 2 APEX trial for zumilokibart in moderate-to-severe atopic dermatitis, meeting primary and secondary endpoints.

Apogee Therapeutics announced first quarter 2026 financial results, highlighting progress in its lead drug candidate zumilokibart and a strong cash position extending runway into 2029.

Apogee Therapeutics announces the resignation of two board members, Andrew Gottesdiener and Peter Harwin, effective May 11, 2026.

Apogee Therapeutics, Inc. successfully priced a public offering of 5.75 million common shares at $70.00 each, expecting net proceeds of $377.4 million.

Apogee Therapeutics, Inc. reported a net loss of $74.1 million for the first quarter of 2026, with significant investments in research and development for its inflammatory and immunology programs.

Apogee Therapeutics reports increased net loss in Q3 2025 but highlights positive clinical data for APG777 and significant capital raise post-quarter end.

Apogee Therapeutics announced positive interim results for its lead programs APG777 and APG808, demonstrating favorable efficacy and extended half-life profiles.

Apogee Therapeutics details its financial performance for Q1 2025, highlighting progress in clinical trials and strategic collaborations.

Apogee Therapeutics reports a net loss of $49 million for Q3 2024, alongside updates on its clinical programs and financial position.

Apogee Therapeutics, a clinical-stage biotech company, released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs.

Apogee Therapeutics' 2025 annual report highlights positive clinical trial data for lead programs in atopic dermatitis and asthma, alongside significant capital raises to fund pipeline development.

Apogee Therapeutics' 10-K filing summarizes the company's financial results for 2024 and highlights the clinical progress of its antibody programs targeting inflammatory and immunology indications.

Apogee Therapeutics outlines its share structure, voting rights, and registration rights in its recent 10-K filing, providing investors with key details about its capital stock.

Jane Henderson, Chief Financial Officer of Apogee Therapeutics, Inc., reported a transaction in 15,000 shares of common stock on July 24, 2026.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported a transaction in 8,000 shares of common stock on July 14, 2026.

Michael Henderson, CEO of Apogee Therapeutics, sold 20,000 shares of common stock for $133.63 per share under a Rule 10b5-1 trading plan, and also gifted 75,046 shares to a donor-advised fund.

Carl Dambkowski, Chief Medical Officer at Apogee Therapeutics, Inc., reported transactions involving the acquisition and disposition of common stock, including trades executed under a Rule 10b5-1 plan.

Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc., reported the sale of 26,400 shares of common stock executed under a pre-arranged Rule 10b5-1 trading plan.

Apogee Therapeutics CEO Michael Henderson reported the sale of 80,000 shares under a pre-arranged 10b5-1 trading plan.

Apogee Therapeutics, Inc. has issued its 2026 proxy statement detailing the upcoming annual meeting, director elections, and executive compensation advisory vote.

Apogee Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, with voting open until June 16, 2025, covering director elections, auditor ratification, and executive compensation advisory vote frequency.

Apogee Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, featuring proposals for director elections, auditor ratification, and executive compensation advisory vote.

Apogee Therapeutics has appointed Lisa Bollinger, M.D., a seasoned drug development expert, to its Board of Directors, effective May 28, 2024.

Apogee Therapeutics has scheduled its 2024 Annual Meeting for June 5, 2024, and is soliciting votes on key proposals including the election of directors and ratification of the company's independent auditor.

Apogee Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 5, 2024, to vote on director elections, auditor ratification, and an option grant to a director.

Apogee Therapeutics has filed a registration statement to offer an additional $80.5 million in common stock, including shares for underwriters' options, following its initial S-1 filing.

Apogee Therapeutics plans to offer 6,000,000 shares of its common stock to fund clinical trials and research programs.

Fairmount Funds Management and related entities updated their beneficial ownership in Apogee Therapeutics, Inc. to 9.99% following a recent public offering.

Fairmount Healthcare Fund II L.P. sold 1.75 million shares of Apogee Therapeutics common stock for $76.30 per share, reducing its beneficial ownership.

Fairmount Healthcare Fund II L.P. entered into a 60-day lock-up agreement for its Apogee Therapeutics shares following a public offering.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 0.9% of Apogee Therapeutics, Inc. common stock as of June 30, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 772,969 shares, representing 1.3% of the outstanding common stock of Apogee Therapeutics Inc.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 4.0% of Apogee Therapeutics Inc.'s common stock as of June 30, 2026.

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 16.8% in Apogee Therapeutics Inc. as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, indicating it no longer holds beneficial ownership in Apogee Therapeutics Inc. following an internal realignment.

T. Rowe Price Investment Management, Inc. has disclosed an 11.3% beneficial ownership stake in Apogee Therapeutics Inc. common stock.